This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).
Aged ≥18 and ≤75 years.
Diagnosed with cutaneous lupus erythematosus (CLE) for at least 3 months before the screening visit.
Biopsy-proven histologically consistent with discoid lupus erythematosus (DLE) and/or subacute cutaneous lupus erythematosus (SCLE).
CLASI activity (CLASI-A) score ≥8 at both the screening and baseline (Day 1) visits.
Specific cutaneous lupus erythematosus subtypes: acute cutaneous lupus erythematosus (ACLE), tumid lupus, lupus panniculitis (deep lupus), chilblain lupus.
Patients with drug-induced cutaneous lupus erythematosus and/or drug-induced systemic lupus erythematosus.
Subjects with active kidney disease 4．Other inflammatory joint or skin diseases or overlap syndrome not caused by systemic lupus erythematosus (SLE) as the primary disease.